| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3615 |
| Trial ID | NCT06078306 |
| Disease | B Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | GDC-0199 |
| Co-treatment | Azacitidine|Venetoclax |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Clinical Trial for the Safety and Efficacy of Induction Chemotherapy With Azacitidine+Venetoclax (VA) and Bridging CD19CD22 CAR-T Therapy in Adult Patients With Newly Diagnosed High-Risk and Ph-negative (Ph-) B-ALL |
| Year | 2024 |
| Country | China |
| Company sponsor | The First Affiliated Hospital of Soochow University |
| Other ID(s) | High Risk B-ALL |
| Cohort 1 | |||||||
|
|||||||